Sulodexide induces hepatocyte growth factor release in humans

European Journal of Pharmacology

Volumn 558, Issue 1-3, 2007, Pages 167-171

  Borawski, Jacek ^a   Dubowski, Miroslaw ^a   Pawlak, Krystyna ^a   Mysliwiec, Michal ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Glycosaminoglycan; Heparin; Hepatocyte growth factor; Human study; Sulodexide

Indexed keywords

SCATTER FACTOR; SULODEXIDE;

ADULT; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ADULT; ANTICOAGULANTS; GLYCOSAMINOGLYCANS; HEPATOCYTE GROWTH FACTOR; HUMANS; INJECTIONS, INTRAVENOUS; MALE;

EID: 33847302393     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.12.009     Document Type: Article

References (38)

1. Abaterusso C., and Gambaro G. The role of glycosaminoglycans and sulodexide in the treatment of diabetic nephropathy. Treat. Endocrinol. 5 (2006) 211-222
2. Achour A., Kacem M., Dibej K., Skhiri H., Bouraoui S., and El May M. One year course of oral sulodexide in the management of diabetic nephropathy. J. Nephrol. 18 (2005) 568-574
3. Borawski J., Naumnik B., and Myśliwiec M. Activation of hepatocyte growth factor/activin A/follistatin system during hemodialysis: role of heparin. Kidney Int. 64 (2003) 2229-2237
4. Cirujeda J.L., and Granado P.C. A study of the safety, efficacy, and efficiency of sulodexide compared with acenocoumarol in secondary prophylaxis in patients with deep venous thrombosis. Angiology 57 (2006) 53-64
5. Coccheri S., Scondotto G., Agnelli G., Aloisi D., Palazzini E., Zamboni V., and Venous arm of the SUAVIS (Sulodexide Arterial Venous Italian Study) Group. Randomized, double blind, multicentre, placebo-controlled study of sulodexide in the treatment of venous leg ulcers. Thromb. Haemost. 87 (2002) 947-952
6. Coccheri S., Scondotto G., Agnelli G., Palazzini E., Zamboni V., and Arterial arm of the SUAVIS (Sulodexide Arterial Venous Italian Study) Group. Sulodexide in the treatment of intermittent claudication. Results of a randomized, double-blind, multicentre, placebo-controlled study. Eur. Heart J. 23 (2002) 1057-1065
7. Condorelli M., Chiarello M., Daggianti A., Penco M., Dalla Volta S., Pengo V., Schivazappa L., Mattioli A.V., Brusoni B., Trotta E., and Bignamini A. IPO-V2: a prospective, multicenter, randomized, comparative clinical investigation of the effects of sulodexide in preventing cardiovascular accidents in the first year after acute myocardial infarction. J. Am. Coll. Cardiol. 23 (1994) 27-34
8. Conway K., Price P., Harding K.G., and Jiang W.G. The molecular and clinical impact of hepatocyte growth factor, its receptor, activators, and inhibitors in wound healing. Wound Repair Regen. 14 (2006) 2-10
9. Date I., Takagi N., Takagi K., Kago T., Matsumoto K., Nakamura T., and Takeo S. Hepatocyte growth factor attenuates cerebral ischemia-induced learning dysfunction. Biochem. Biophys. Res. Commun. 319 (2004) 1152-1158
10. Elsayed E., and Becker R.C. The impact of heparin compounds on cellular inflammatory responses: a construct for future investigation and pharmaceutical development. J. Thromb. Thrombolysis 15 (2003) 11-18
11. Errichi B.M., Cesarone M.R., Belcaro G., Marinucci R., Ricci A., Ippolito A., Brandolini R., Vinciguerra G., Dugall M., Felicita A., Pellegrini L., Gizzi G., Ruffini M., Acerbi G., Bavera P., Renzo A.D., Corsi M., Scoccianti M., Hosoi M., and Lania M. Prevention of recurrent deep venous thrombosis with sulodexide: the SanVal registry. Angiology 55 (2004) 243-249
12. Fracasso A., Baggio B., Masiero M., Bonfante L., Bazzato G., Feriani M., and Gambaro G. Effect of oral treatment with glycosaminoglycan sulodexide on peritoneal transport in CAPD patients. Perit. Dial. Int. 23 (2003) 595-599
13. Funakoshi H., and Nakamura T. Hepatocyte growth factor: from diagnosis to clinical applications. Clin. Chim. Acta 327 (2003) 1-23
14. Gambaro G., Kinalska I., Oksa A., Pont'uch P., Hertlová M., Olsovsky J., Manitius J., Fedele D., Czekalski S., Perusicová J., Skrha J., Taton J., Grzeszczak W., and Crepaldi G. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. J. Am. Soc. Nephrol. 13 (2002) 1615-1625
15. Harenberg J. Review of pharmacodynamics, pharmacokinetics, and therapeutic properties of sulodexide. Med. Res. Rev. 18 (1998) 1-20
16. Ido A., Numata M., Kodama M., and Tsubouchi H. Mucosal repair and growth factors: hepatocyte growth factor as an innovative therapy for inflammatory bowel disease. J. Gastroenterol. 40 (2005) 925-931
17. Izumida Y., Aoki T., Yasuda D., Koizumi T., Suganuma C., Saito K., Murai N., Shimizu Y., Hayashi K., Odaira M., Kusano T., Kushima M., and Kusano M. Hepatocyte growth factor is constitutively produced by donor-derived bone marrow cells and promotes regeneration of pancreatic beta-cells. Biochem. Biophys. Res. Commun. 333 (2005) 273-282
18. Jayasankar V., Woo Y.J., Pirolli T.J., Bish L.T., Berry M.F., Burdick J., Gardner T.J., and Sweeney H.L. Induction of angiogenesis and inhibition of apoptosis by hepatocyte growth factor effectively treats postischemic heart failure. J. Card. Surg. 20 (2005) 93-101
19. Kim W.H., Matsumoto K., Bessho K., and Nakamura T. Growth inhibition and apoptosis in liver myofibroblasts promoted by hepatocyte growth factor leads to resolution from liver cirrhosis. Am. J. Pathol. 166 (2005) 1017-1028
20. Kinoshita M., Miyamoto T., Ohashi N., Sasayama S., and Matsumori A. Thrombosis increases circulatory hepatocyte growth factor by degranulation of mast cells. Circulation 106 (2002) 3133-3138
21. Kristová V., Kriška M., Babál P., Djibril M.N., Slámová J., and Krustansky A. Evaluation of endothelium-protective effects of drugs in experimental model of endothelial damage. Physiol. Res. 49 (2000) 123-128
22. Lauver D.A., Booth E.A., White A.J., Paradosu E., and Lucchesi B.R. Sulodexide attenuates myocardial ischemia/reperfusion injury and the deposition of C-reactive protein in areas of infarction without affecting hemostasis. J. Pharmacol. Exp. Ther. 312 (2005) 794-800
23. Liu Y. Hepatocyte growth factor in kidney fibrosis: therapeutic potential and mechanisms of action. Am. J. Physiol. Renal Physiol. 287 (2004) 7-16
24. Lyon M., Deakin J.A., and Gallagher J.T. The mode of action of heparan and dermatan sulfates in the regulation of hepatocyte growth factor/scatter factor. J. Biol. Chem. 277 (2002) 1040-1046
25. Matsuo K., Maeda Y., Naiki Y., Matsuoka T., Tamai Y., Yonekawa S., Sakaguchi M., Iwamoto I., Hasegawa H., Matsumoto K., Nakamura T., and Kanamaru A. Possible effects of hepatocyte growth factor for the prevention of peritoneal fibrosis. Nephron Exp. Nephrol. 99 (2005) 87-94
26. McKinnon H., Gherardi E., Reidy M., and Bowyer D. Hepatocyte growth factor/scatter factor and MET are involved in arterial repair and atherogenesis. Am. J. Pathol. 168 (2006) 340-348
27. Morishita R., Aoki M., Hashiya N., Makino H., Yamasaki K., Azuma J., Sawa Y., Matsuda H., Kaneda Y., and Ogihara T. Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease. Hypertension 44 (2004) 203-209
28. Norrby K. Low-molecular-weight heparins and angiogenesis. APMIS 114 (2006) 79-102
29. Ofosu F.A. Pharmacological actions of sulodexide. Semin. Thromb. Hemost. 24 (1998) 127-138
30. Park H.Y., Kang S., Kim G.Y., Jang Y., Kwon H.M., Shim W.H., Cho S.Y., and Cho S.H. Inhibition of neointimal proliferation of rat carotid artery by sulodexide. J. Korean Med. Sci. 12 (1997) 210-214
31. Parnetti L., Mari D., Abate G., Balestreri R., Cucinotta D., Coppola R., Cherubini A., Ferrari P., and Senin U. Vascular dementia Italian sulodexide study (VA.D.I.S.S.). Clinical and biological results. Thromb. Res. 87 (1997) 225-233
32. Sakaguchi G., Tambara K., Sakakibara Y., Ozeki M., Yamamoto M., Premaratne G., Lin X., Hasegawa K., Tabata Y., Nishimura K., and Komeda M. Control-released hepatocyte growth factor prevents the progression of heart failure in stroke-prone spontaneously hypertensive rats. Ann. Thorac. Surg. 79 (2005) 1627-1634
33. Salbach P.B., Brückmann M., Turovets O., Kreuzer J., Kubler W., and Walter-Sack I. Heparin-mediated selective release of hepatocyte growth factor in humans. Br. J. Clin. Pharmacol. 50 (2000) 221-226
34. Seidel C., Hjorth-Hansen H., Bendz B., Borset M., Sandset P.M., Hansen J.B., Sundan A., and Waage A. Hepatocyte growth factor in serum after injection of unfractionated and low molecular weight heparin in healthy individuals. Br. J. Haematol. 105 (1999) 641-647
35. Shimamura M., Sato N., Waguri S., Uchiyama Y., Hayashi T., Iida H., Nakamura T., Ogihara T., Kaneda Y., and Morishita R. Gene transfer of hepatocyte growth factor improves learning and memory in the chronic stage of cerebral infarction. Hypertension 47 (2006) 742-751
36. Watanabe M., Ebina M., Orson F.M., Nakamura A., Kubota K., Koinuma D., Akiyama K., Maemondo M., Okouchi S., Tahara M., Matsumoto K., Nakamura T., and Nukiwa T. Hepatocyte growth factor gene transfer to alveolar septa for effective suppression of lung fibrosis. Molec. Ther. 12 (2005) 58-67
37. Xia J.L., Dai C., Michalopoulos G.K., and Liu Y. Hepatocyte growth factor attenuates liver fibrosis induced by bile duct ligation. Am. J. Pathol. 168 (2006) 1500-1512
38. Zhou Y.J., Wang J.H., and Zhang J. Hepatocyte growth factor protects human endothelial cells against advanced glycation end products-induced apoptosis. Biochem. Biophys. Res. Commun. 344 (2006) 648-656